MOLECULAR IDENTIFICATION AND IN-VITRO SUSCEPTIBILITY OF CANDIDA ALBICANS AND C. DUBLINIENSIS ISOLATED FROM IMMUNOCOMPROMISED PATIENTS

Background: Yeasts are increasingly implicated in serious systemic infections. The aim of this study was to identify Candida albicans and C. dubliniensis from isolates of immunocompromised patients and evaluate the in vitro antifungal activities of them against antifungal agents. Methods: One hundred and seventy eight C. albicans were isolated by routine methods from 403 immunocompromised patients. All isolated C. albicans were inoculated on CHROMagar Candida medium. The carbohydrate assimilation patterns of all the isolates were studied, using the API 32C system. To identify C. albicans and C. dubliniensis, PCR was done by specific primers. The susceptibility test for the isolates was performed by a broth microdilution assay, according to the Clinical and Laboratory Standard Institute. Results: Of 178 isolates C. albicans, six were C. dubliniensis with PCR assay, and 7% were resistant to amphotericin B, 4.6% to fluconazole, 7% to itraconazole, 1% to nystatin, 2.3% to voriconazole, and 7% to ketoconazole. None of the C. dubliniensis isolates were resistant to the six anti-fungal agents. Conclusion: It would be convenient to carry out antifungal susceptibility studies in order to establish the in-vitro activities of antifungal agents against local isolates and also to detect shifts toward resistance as early as possible.

[1]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[2]  C. Chan,et al.  IN VITRO ACTIVITY OF FLUCONAZOLE AND VORICONAZOLE AGAINST INVASIVE CANDIDA ALBICANS ISOLATES IN PATIENTS WITH CANDIDAEMIA FROM 2001–2005 IN HONG KONG , 2006 .

[3]  W. Coulter,et al.  In vitro susceptibility of oral Candida to seven antifungal agents. , 2005, Oral microbiology and immunology.

[4]  H. Yamaguchi,et al.  Differentiation of Candida albicans and Candida dubliniensis using a single-enzyme PCR-RFLP method. , 2005, Japanese journal of infectious diseases.

[5]  Yolanda Morera López,et al.  Estudio de la sensibilidad in vitro de aislamientos clínicos de mohos y levaduras a itraconazol y voriconazol , 2005 .

[6]  M. Yılmaz,et al.  [Molecular identification of Candida albicans and Candida dubliniensis strains isolated from clinical samples]. , 2005, Mikrobiyoloji bulteni.

[7]  S. Cesur,et al.  In vitro susceptibility of Candida species isolated from blood culture to some antifungal agents. , 2005, Japanese journal of infectious diseases.

[8]  H. Goossens,et al.  Use of specialised isolation media for recognition and identification ofCandida dubliniensis isolates from HIV-infected patients , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[9]  S. Essayag,et al.  DETECTION OF CANDID ADUBLINIENSIS IN VENEZUELA , 2005 .

[10]  J. M. Torres-Rodríguez,et al.  [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole]. , 2005, Revista iberoamericana de micologia.

[11]  J. Bagg,et al.  High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer , 2003, Palliative medicine.

[12]  J. Perfect,et al.  Global Distribution and Outcomes for Candida Species Causing Invasive Candidiasis: Results from an International Randomized Double-Blind Study of Caspofungin Versus Amphotericin B for the Treatment of Invasive Candidiasis , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[13]  A. Colombo,et al.  Candida dubliniensis identification in Brazilian yeast stock collection. , 2003, Memorias do Instituto Oswaldo Cruz.

[14]  J. Rex,et al.  Correlation between E-Test, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility Testing of Fluconazole and Voriconazole , 2003, Antimicrobial Agents and Chemotherapy.

[15]  M. Pfaller,et al.  Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001 , 2003, Journal of Clinical Microbiology.

[16]  M. Pfaller,et al.  Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. , 2002, Diagnostic microbiology and infectious disease.

[17]  D. Massart,et al.  Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. , 2001, The Journal of antimicrobial chemotherapy.

[18]  F. Dalle,et al.  Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. , 2001, The Journal of hospital infection.

[19]  G. Kronvall,et al.  Fluconazole and Voriconazole Multidisk Testing ofCandida Species for Disk Test Calibration and MIC Estimation , 2001, Journal of Clinical Microbiology.

[20]  M. Ghannoum,et al.  Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents , 2000, Journal of Clinical Microbiology.

[21]  M. Wong,et al.  Rapid Identification of Candida dubliniensis Using a Species-Specific Molecular Beacon , 2000, Journal of Clinical Microbiology.

[22]  Ronald N. Jones,et al.  Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998 , 2000, Antimicrobial Agents and Chemotherapy.

[23]  D. Soll,et al.  Identification of Candida dubliniensis Based on Temperature and Utilization of Xylose and α-Methyl-d-Glucoside as Determined with the API 20C AUX and Vitek YBC Systems , 1999, Journal of Clinical Microbiology.

[24]  J. Pemán,et al.  Fluconazole Susceptibilities of Bloodstream Candidasp. Isolates as Determined by National Committee for Clinical Laboratory Standards Method M27-A and Two Other Methods , 1999, Journal of Clinical Microbiology.

[25]  M. Brandt,et al.  Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. , 1999, Diagnostic microbiology and infectious disease.

[26]  A. Bolmström,et al.  Evaluation of the Etest Method for Determining Fluconazole Susceptibilities of 402 Clinical Yeast Isolates by Using Three Different Agar Media , 1998, Journal of Clinical Microbiology.

[27]  D. Sullivan,et al.  Simple, Inexpensive, Reliable Method for Differentiation of Candida dubliniensis fromCandida albicans , 1998, Journal of Clinical Microbiology.

[28]  C. Kurtzman,et al.  Rapid Identification of Candida albicansand Other Human Pathogenic Yeasts by Using Short Oligonucleotides in a PCR , 1998, Journal of Clinical Microbiology.

[29]  R. Bowden,et al.  Panfungal PCR Assay for Detection of Fungal Infection in Human Blood Specimens , 1998, Journal of Clinical Microbiology.

[30]  Elizabeth M. Johnson,et al.  Comparative Evaluation of FUNGITEST and Broth Microdilution Methods for Antifungal Drug Susceptibility Testing of Candida Species and Cryptococcus neoformans , 1998, Journal of Clinical Microbiology.

[31]  D. Sullivan,et al.  Candida dubliniensis: Characteristics and Identification , 1998, Journal of Clinical Microbiology.

[32]  M. Rinaldi,et al.  In vitro evaluation of voriconazole against some clinically important fungi , 1997, Antimicrobial agents and chemotherapy.

[33]  G. Moran,et al.  Candidiasis: the emergence of a novel species, Candida dubliniensis , 1997, AIDS.

[34]  M. Henman,et al.  Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro , 1997, Antimicrobial agents and chemotherapy.

[35]  D. Coleman,et al.  Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. , 1995, Microbiology.

[36]  J. Still,et al.  A comparison of susceptibility to five antifungal agents of yeast cultures from burn patients. , 1995, Burns : journal of the International Society for Burn Injuries.